These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 32946006

  • 1. Podocyte sphingomyelin phosphodiesterase acid-like 3b decreases among children with idiopathic nephrotic syndrome.
    Watanabe S, Hirono K, Aizawa T, Tsugawa K, Joh K, Imaizumi T, Tanaka H.
    Clin Exp Nephrol; 2021 Jan; 25(1):44-51. PubMed ID: 32946006
    [Abstract] [Full Text] [Related]

  • 2. Urinary excretion of sphingomyelinase phosphodiesterase acid-like 3b in children with intractable nephrotic syndrome.
    Watanabe S, Tsugawa K, Tsuruga K, Imaizumi T, Tanaka H.
    Pediatr Int; 2017 Oct; 59(10):1112-1115. PubMed ID: 29081073
    [Abstract] [Full Text] [Related]

  • 3. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.
    Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW.
    Sci Transl Med; 2011 Jun 01; 3(85):85ra46. PubMed ID: 21632984
    [Abstract] [Full Text] [Related]

  • 4. The Importance of Sphingomyelin Phosphodiesterase Acid-Like 3b (SMPDL-3b) Levels in Kidney Biopsy Specimens of Children With Nephrotic Syndrome.
    Kaya M, Girişgen İ, Yalçın N, Becerir T, Şenol H, Gülten G, Yüksel S.
    Fetal Pediatr Pathol; 2023 Dec 01; 42(6):936-949. PubMed ID: 37818552
    [Abstract] [Full Text] [Related]

  • 5. Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes.
    Takahashi Y, Ikezumi Y, Saitoh A.
    Nephrology (Carlton); 2017 Jan 01; 22(1):49-57. PubMed ID: 26833819
    [Abstract] [Full Text] [Related]

  • 6. Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation.
    Tasaki M, Shimizu A, Hanekamp I, Torabi R, Villani V, Yamada K.
    J Am Soc Nephrol; 2014 Apr 01; 25(4):737-44. PubMed ID: 24459229
    [Abstract] [Full Text] [Related]

  • 7. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.
    Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM.
    Kidney Int; 2013 Nov 01; 84(5):1025-33. PubMed ID: 23739238
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Daily urinary interleukin-11 excretion correlated with proteinuria in IgA nephropathy and lupus nephritis.
    Chien JW, Chen WL, Tsui YG, Lee MC, Lin AY, Lin CY.
    Pediatr Nephrol; 2006 Apr 01; 21(4):490-6. PubMed ID: 16528544
    [Abstract] [Full Text] [Related]

  • 12. Apical cell membranes are shed into urine from injured podocytes: a novel phenomenon of podocyte injury.
    Hara M, Yanagihara T, Kihara I, Higashi K, Fujimoto K, Kajita T.
    J Am Soc Nephrol; 2005 Feb 01; 16(2):408-16. PubMed ID: 15625073
    [Abstract] [Full Text] [Related]

  • 13. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.
    Madan A, Mijovic-Das S, Stankovic A, Teehan G, Milward AS, Khastgir A.
    BMC Nephrol; 2016 Mar 31; 17():37. PubMed ID: 27036111
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-18 in urine and serum of children with idiopathic nephrotic syndrome.
    Kiliś-Pstrusińska K, Medyńska A, Zwolińska D, Wawro A.
    Kidney Blood Press Res; 2008 Mar 31; 31(2):122-6. PubMed ID: 18391570
    [Abstract] [Full Text] [Related]

  • 15. [Interleukin-17 concentration in serum and urine of children with idiopathic nephrotic syndrome].
    Kiliś-Pstrusińska K, Zwolińska D, Medyńska A, Wawro A, Kordecki H.
    Przegl Lek; 2006 Mar 31; 63 Suppl 3():198-200. PubMed ID: 16898529
    [Abstract] [Full Text] [Related]

  • 16. Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes.
    Ahmad A, Mitrofanova A, Bielawski J, Yang Y, Marples B, Fornoni A, Zeidan YH.
    FASEB J; 2017 Feb 31; 31(2):771-780. PubMed ID: 27836988
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ectopic expression of CLDN2 in podocytes is associated with childhood onset nephrotic syndrome.
    Kanno S, Kume Y, Maeda R, Ono A, Suyama K, Kawasaki Y, Hosoya M.
    Pediatr Res; 2019 Oct 31; 86(4):485-491. PubMed ID: 31086291
    [Abstract] [Full Text] [Related]

  • 19. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
    Ravani P, Bonanni A, Ghiggeri GM.
    BMJ Open; 2017 Mar 17; 7(3):e013319. PubMed ID: 28314744
    [Abstract] [Full Text] [Related]

  • 20. Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice.
    Jamin A, Berthelot L, Couderc A, Chemouny JM, Boedec E, Dehoux L, Abbad L, Dossier C, Daugas E, Monteiro RC, Deschênes G.
    J Autoimmun; 2018 May 17; 89():149-161. PubMed ID: 29307588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.